The Podocalyxin/Ezrin complex induces heightened MMP expression, enhanced MAPK and PI3K activity, culminating in a more aggressive PCa phenotype (Sizemore et al., 2007). The gene discussed is EZR; the disease is posterior cortical atrophy.